Literature DB >> 24951762

Pulmonary arterial hypertension: the clinical syndrome.

Yen-Chun Lai1, Karin C Potoka1, Hunter C Champion1, Ana L Mora1, Mark T Gladwin2.   

Abstract

Pulmonary arterial hypertension is a progressive disorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, resulting in increased pulmonary vascular resistance and pulmonary pressures. This leads to reduced cardiac output, right heart failure, and ultimately death. In this review, we attempt to answer some important questions commonly asked by patients diagnosed with pulmonary arterial hypertension pertaining to the disease, and aim to provide an explanation in terms of classification, diagnosis, pathophysiology, genetic causes, demographics, and prognostic factors. Furthermore, important molecular pathways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial and smooth muscle proliferation.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  hemodynamics; hypertension, pulmonary; nitric oxide

Mesh:

Substances:

Year:  2014        PMID: 24951762      PMCID: PMC4096686          DOI: 10.1161/CIRCRESAHA.115.301146

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  121 in total

1.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

Authors:  C Rubens; R Ewert; M Halank; R Wensel; H D Orzechowski; H P Schultheiss; G Hoeffken
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

2.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.

Authors:  T C Yeo; K S Dujardin; C Tei; D W Mahoney; M D McGoon; J B Seward
Journal:  Am J Cardiol       Date:  1998-05-01       Impact factor: 2.778

3.  Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.

Authors:  Jeffrey P Khoo; Lan Zhao; Nicholas J Alp; Jennifer K Bendall; Taija Nicoli; Kirk Rockett; Martin R Wilkins; Keith M Channon
Journal:  Circulation       Date:  2005-04-11       Impact factor: 29.690

4.  Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2.

Authors:  Gábor Csányi; Eugenia Cifuentes-Pagano; Imad Al Ghouleh; Daniel J Ranayhossaini; Loreto Egaña; Lucia R Lopes; Heather M Jackson; Eric E Kelley; Patrick J Pagano
Journal:  Free Radic Biol Med       Date:  2011-04-17       Impact factor: 7.376

5.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

6.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

7.  B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.

Authors:  A Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher Frampton; John Turner; Ian G Crozier; Timothy G Yandle
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  Diversity in mitochondrial function explains differences in vascular oxygen sensing.

Authors:  Evangelos D Michelakis; Vaclav Hampl; Ali Nsair; XiCheng Wu; Gwyneth Harry; Al Haromy; Rachita Gurtu; Stephen L Archer
Journal:  Circ Res       Date:  2002-06-28       Impact factor: 17.367

9.  cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla.

Authors:  T Namba; H Oida; Y Sugimoto; A Kakizuka; M Negishi; A Ichikawa; S Narumiya
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

10.  Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.

Authors:  James West; Karen Fagan; Wolfgang Steudel; Brian Fouty; Kirk Lane; Julie Harral; Marloes Hoedt-Miller; Yuji Tada; John Ozimek; Rubin Tuder; David M Rodman
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

View more
  121 in total

1.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

2.  Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.

Authors:  Shirin Bruderer; Marc Petersen-Sylla; Margaux Boehler; Tatiana Remeňová; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

Review 3.  NADPH oxidase: its potential role in promotion of pulmonary arterial hypertension.

Authors:  Jing-Jie Peng; Bin Liu; Jin-Yun Xu; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

Review 4.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

5.  Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension.

Authors:  Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

Review 6.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 7.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

8.  Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.

Authors:  Hiroshi Suzuki; Haruo Hanawa; Tsukasa Torigoe; Seiichi Sato
Journal:  J Cardiol Cases       Date:  2017-04-26

Review 9.  The COP9 signalosome and vascular function: intriguing possibilities?

Authors:  Douglas S Martin; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

Review 10.  Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Authors:  Tara Elizabeth Scott; Barbara K Kemp-Harper; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2018-06-27       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.